Literature DB >> 18178794

Slowing nephropathy progression: focus on proteinuria reduction.

George L Bakris1.   

Abstract

Blood pressure control reduces decline of kidney function. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers offer renoprotection to a small extent beyond that attributable to blood pressure lowering. These agents also reduce proteinuria, a risk marker for renal disease progression. Accumulating evidence indicates that their antiproteinuric effect correlates with their additional renal benefits.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18178794      PMCID： PMC3152266          DOI： 10.2215/CJN.03250807

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


  30 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy.

Authors:  M F Yuyun; S F Dinneen; O M Edwards; E Wood; N J Wareham
Journal:  Diabet Med       Date:  2003-04       Impact factor: 4.359

3.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

5.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

Review 6.  Is proteinuria a plausible target of therapy?

Authors:  Dave C Y Chua; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

7.  Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.

Authors:  Holly J Kramer; Quan Dong Nguyen; Gary Curhan; Chi-Yuan Hsu
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272

8.  Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

9.  Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.

Authors:  Koon Teo; Salim Yusuf; Peter Sleight; Craig Anderson; Farouk Mookadam; Barbara Ramos; Lutz Hilbrich; Janice Pogue; Helmut Schumacher
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

Review 10.  ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence.

Authors:  George L Bakris; Matthew Weir
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738
View more
  42 in total

1.  Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction.

Authors:  Luis F Quintana; Josep M Campistol; Maria P Alcolea; Elisenda Bañon-Maneus; Amandaé Sol-González; Pedro R Cutillas
Journal:  Mol Cell Proteomics       Date:  2009-04-07       Impact factor: 5.911

2.  O-GlcNAcylation reduces proximal tubule protein reabsorption and promotes proteinuria in spontaneously hypertensive rats.

Authors:  Rodrigo Pacheco Silva-Aguiar; Nathália C F Bezerra; Miguel C Lucena; Gabriela M Sirtoli; Roberto T Sudo; Gisele Zapata-Sudo; Christina M Takiya; Ana Acacia S Pinheiro; Wagner Barbosa Dias; Celso Caruso-Neves
Journal:  J Biol Chem       Date:  2018-06-28       Impact factor: 5.157

3.  ESCAPE: From hypertension to renal failure.

Authors:  Helmy M Siragy
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 4.  Stop chronic kidney disease progression: Time is approaching.

Authors:  Usama Abdel Azim Sharaf El Din; Mona Mansour Salem; Dina Ossama Abdulazim
Journal:  World J Nephrol       Date:  2016-05-06

5.  Risk profiles of progression in primary focal segmental glomerulosclerosis.

Authors:  Lori L Travis; James C M Chan
Journal:  World J Pediatr       Date:  2010-08-13       Impact factor: 2.764

6.  Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study.

Authors:  Jocelyn S Gandelman; Omair A Khan; Megan M Shuey; Jacquelyn E Neal; Elizabeth McNeer; Alyson Dickson; April Barnado; Li Wang; Prathima Anandi; William D Dupont; C Michael Stein; Cecilia P Chung
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-04       Impact factor: 4.794

Review 7.  Homocysteine in renovascular complications: hydrogen sulfide is a modulator and plausible anaerobic ATP generator.

Authors:  Utpal Sen; Sathnur B Pushpakumar; Matthew A Amin; Suresh C Tyagi
Journal:  Nitric Oxide       Date:  2014-06-22       Impact factor: 4.427

8.  Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease.

Authors:  Taro Hoshino; Susumu Ookawara; Haruhisa Miyazawa; Kiyonori Ito; Yuichiro Ueda; Yoshio Kaku; Keiji Hirai; Honami Mori; Izumi Yoshida; Kaoru Tabei
Journal:  Clin Exp Nephrol       Date:  2014-05-13       Impact factor: 2.801

9.  Generating a Podocyte-Specific Neonatal F Receptor (FcRn) Knockout Mouse.

Authors:  Judith Blaine
Journal:  Methods Mol Biol       Date:  2021

10.  Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD) study: Protocol and baseline characteristics of a randomized controlled trial.

Authors:  Clarissa J Diamantidis; Hayden B Bosworth; Megan M Oakes; Clemontina A Davenport; Jane F Pendergast; Sejal Patel; Jivan Moaddeb; Huiman X Barnhart; Peter D Merrill; Khaula Baloch; Matthew J Crowley; Uptal D Patel
Journal:  Contemp Clin Trials       Date:  2018-04-10       Impact factor: 2.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.